As previously announced, FDA is conducting a review of the Clozapine REMS to determine if the requirements for blood monitoring of neutropenia can be modified “to minimize burden on patients, pharmacies, and prescribers while maintaining safe use of clozapine.”
The American Psychiatric Association (APA) will host a Policy and Practice Insight webinar about the clozapine REMS on January 17, 2024 at noon EST.
The webinar will cover an overview of the FDA’s Clozapine REMS program, highlighting current research and data from providers and patients, and sharing how the APA has been advocating for change.
Providers, clinicians, families, and advocates are encouraged to attend this important event.
Please register by clicking “Register Today” at the link below:
This webinar will be facilitated by:
Robert O. Cotes, MD – SMI Adviser Physician Expert, Emory University School of Medicine in the Department of Psychiatry and Behavioral Sciences
Teri Brister, PhD, LPC – SMI Patient and Family Engagement Expert, National Alliance on Mental Illness (NAMI)
Brooke Trainum – Director of Practice Policy, American Psychiatric Association (APA)
On December 21, 2023, the APA’s Psychiatric News online publication released an important update on the APA’s efforts to reduce treatment barriers associated with the clozapine REMS and the exaggerated risks of clozapine-induced neutropenia. Read the update here:
Thank you to the APA and NAMI for your persistent efforts toward our cause!
The Angry Moms